GLP-2(1-33) (human)
(Synonyms: 人GLP-2肽,GLP-2 (human); Glucagon-like peptide 2 (human)) 目录号 : GC16646
GLP-2(1-33) (human)是一种内分泌激素，由肠道L细胞在营养摄入后释放。
Cas No.:223460-79-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
GLP-2(1-33) (human) is an endocrine hormone that is released from the intestinal L-cell in response to nutrient ingestion. GLP-2 has many beneficial effects in the gut, including stimulation of intestinal epithelial cell proliferation, as well as enhancing the barrier function of the epithelium and improving both nutrient absorption and blood flow[1]. GLP-2 can be used in a broad variety of intestinal diseases characterized by intestinal damage and insufficiency[2].
GLP-2(1-33) (human) increase the expression of IGFBP-4 mRNA in the FRIC cultures by 40.8 ± 15.2% (P < 0.05)[1].
GLP-2(1-33) (human) (0.25mg/kg/time, 1 time, i.p.) can regulate the release of stored TG from the enterocyte[3]. GLP-2(1-33) (human) (400µg/kg, 2 times/day, 10 days, s.c.) significant increase (p-value: <0.001)) the intestinal growth in Transgenic female TgN (GCG.DTR) mice[4].
References:
[1] Austin K, Imam NA, Pintar JE, et al. IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestine. Endocrinology. 2015 Feb 1;156(2):429-36.
[2] Wallis K, Walters JR, Forbes A. glucagon‐like peptide 2–current applications and future directions. Alimentary pharmacology & therapeutics. 2007 Feb;25(4):365-72.
[3] Hsieh J, Trajcevski KE, Farr SL, et al. Glucagon-like peptide 2 (GLP-2) stimulates postprandial chylomicron production and postabsorptive release of intestinal triglyceride storage pools via induction of nitric oxide signaling in male hamsters and mice. Endocrinology. 2015 Oct 1;156(10):3538-47.
[4] Gadgaard S, Windeløv JA, Schiellerup SP, et al. Long-acting agonists of human and rodent GLP-2 receptors for studies of the physiology and pharmacological potential of the GLP-2 system. Biomedicine & Pharmacotherapy. 2023 Apr 1;160:114383.
GLP-2(1-33) (human)是一种内分泌激素，由肠道L细胞在营养摄入后释放。GLP-2在肠道中具有许多有益作用，包括刺激肠上皮细胞增殖，增强上皮屏障功能，改善营养吸收和血流[1]。GLP-2可用于多种以肠道损伤和功能不全为特征的肠道疾病[2]。
GLP-2(1-33) (human)使FRIC培养物中IGFBP-4 mRNA的表达增加40.8 ± 15.2%（P < 0.05）[1]。
GLP-2(1-33) (human)（0.25mg/kg/次，1次，腹腔注射）可调节肠细胞释放储存的TG[3]。GLP-2(1-33) (human)（400µg/kg，2次/天，10天，皮下注射）显著增加（p值：<0.001）转基因雌性TgN（GCG.DTR）小鼠的肠道生长[4]。
| Cell experiment [1]: | |
Cell lines | Fetal rat intestinal cells |
Preparation Method | Fetal rat intestinal cells (FRICs) are collected by enzymatical digestion of whole fetal rat intestines (mixed sex) and cultured overnight in DMEM containing 4.5g/L glucose, 5% fetal bovine serum, and 40U/mL penicillin and 40μg/mL streptomycin in 10cm plates. Cells are then treated with GLP-2(1-33) (human) (10-8M) or vehicle in low-glucose DMEM with 0.5% FBS for 0.5 to 24 hours. |
Reaction Conditions | 10-8M, 0.5-24 hours |
Applications | GLP-2(1-33) (human) increase the expression of IGFBP-4 mRNA in the FRIC cultures by 40.8 ± 15.2% (P < 0.05). |
| Animal experiment [2]: | |
Animal models | Hamsters that underwent intraduodenal catheterization |
Preparation Method | Hamsters that undergo intraduodenal catheterization (idc) are allowed 7 days of recovery before jugular vein catheterization. For postprandial experiments, conscious fasted (16h) hamsters receive a 75mmol/kg iv bolus of L-NAME. After 10 minutes, baseline blood sample is collected (time 0), followed by an oralgastric gavage of 3μL Ci [9,10-3H(N)] triolein in 200μL olive oil. At t=10 minutes, F-127 is given ip (1g/kg) to inhibit peripheral TG-rich lipoprotein (TRL) catabolism. At t=20 minutes, the hamsters receive ip injections of either PBS or 0.25mg/kg GLP-2(1-33) (human). Blood (400μL) is collected every 30 minutes for 2 hours. Blood is centrifuged at 6000rpm for 10 minutes at 4°C to isolate plasma. Radioactivity is assessed using a liquid scintillation counter. |
Dosage form | 0.25mg/kg/time, 1 time, i.p. |
Applications | GLP-2(1-33) (human) can regulate the release of stored TG from the enterocyte. |
References: | |
| Cas No. | 223460-79-5 | SDF | |
| 别名 | 人GLP-2肽,GLP-2 (human); Glucagon-like peptide 2 (human) | ||
| 分子式 | C165H254N44O55S | 分子量 | 3766.14 |
| 溶解度 | Soluble to 1 mg/ml in 5% NH4OH / sterile water | 储存条件 | Desiccate at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2655 mL | 1.3276 mL | 2.6552 mL |
| 5 mM | 0.0531 mL | 0.2655 mL | 0.531 mL |
| 10 mM | 0.0266 mL | 0.1328 mL | 0.2655 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet